PM14, IRINOTECAN
PM14-A-002-20
Phase 2 small_molecule active
Quick answer
PM14, IRINOTECAN for Patients with Selected Advanced Solid Tumors is a Phase 2 program (small_molecule) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lacuna Pharma Pty Ltd
- Indication
- Patients with Selected Advanced Solid Tumors
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active